What is the market price of one bottle of semaglutide injection?
Semaglutide injection (Wegovy), as a GLP-1 receptor agonist drug, has been widely used to treat obesity, overweight, type 2 diabetes and other diseases. Semaglutide is an effective medication option for patients who have difficulty losing weight through diet and exercise. It helps patients effectively control their weight by reducing appetite, delaying gastric emptying, and increasing insulin secretion.

The main indications for semaglutide include adults with obesity, overweight and type 2 diabetes. It serves as an auxiliary drug in comprehensive treatment to help patients lose weight and can significantly improve blood sugar control in patients with type 2 diabetes. For obese patients with metabolic diseases such as hyperglycemia and diabetes, the use of semaglutide can help reduce the risk of cardiovascular events.
In addition, semaglutide can also be used as a long-term management option for the treatment of adult obesity. In clinical applications, semaglutide is often used in a comprehensive management program combined with diet control and exercise.
In China, semaglutide injection has been launched and has been included in medical insurance. Its market price is generally between RMB 1,000-2,000. The specific price may vary depending on the region, sales channel and drug specifications (such as 1.5ml and 3ml). The current two common specifications of semaglutide injection are 1.5ml and 3ml, and the price of each injection is generally around more than 1,000 yuan. In overseas markets, the price of semaglutide is relatively high, usually selling for more than one thousand US dollars per box. Therefore, patients also need to consider the cost of the drug when choosing whether to use the drug.
In general, semaglutide injection, as an innovative weight loss drug, has been widely used and recognized in the treatment field at home and abroad. It has shown good results in weight control, diabetes management and cardiovascular risk reduction, and as treatment continues to advance, patients' health management can also be effectively improved.
Reference materials:https://www.drugs.com
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)